Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of grazoprevir + elbasvir in treatment-naive chronic hepatitis C
2014-000137-22Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of grazoprevir and elbasvir in hepatitis C virus infection (2 arms), sponsored by Merck & Co. Primary endpoint: SVR12 rate. Started Apr 2014; status: completed.
02
Drugs
grazoprevirelbasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2014-000137-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000137-22.